share_log

ImmunoGen Announced Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO; Said Patient-Reported Outcomes With Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile

ImmunoGen Announced Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO; Said Patient-Reported Outcomes With Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile

NigoGen宣布在ESMO评估Mirvetuximab Soravtansine治疗卵巢癌的额外分析;说患者报告的Mirvetuximab与Forward I研究中化疗的结果加强了分化的耐受性
Benzinga Real-time News ·  2022/09/11 07:58
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from an analysis of patient-reported outcomes (PROs) with mirvetuximab soravtansine (mirvetuximab) versus chemotherapy in the randomized Phase 3 FORWARD I study in platinum-resistant ovarian cancer. The Company also announced population pharmacokinetic (PK) and exposure response (ER) analyses across multiple clinical trials evaluating mirvetuximab monotherapy in folate receptor alpha (FRα)-positive ovarian cancer. These findings will be highlighted in three posters at the European Society for Medical Oncology (ESMO) Congress in Paris, France. "The data presented at...
亚洲网加利福尼亚州圣何塞10月23日电治疗癌症的抗体-药物结合物(ADC)领域不断扩大的领先企业免疫遗传公司(纳斯达克市场代码:IMGN)今天宣布,在对铂耐药的卵巢癌进行的随机3期FORD I研究中,...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发